About US
Contact us
-
Sanofi's Dupixent set for $2.5B in peak asthma sales after scoring winning label: analystEven as its diabetes unit struggles, Sanofi has made strides on the market with Dupixent since launching last year in eczema. Now, with an FDAapproval(PDF) late Friday in asthma, one analyst believes2018/10/23
-
Consumer deal fever hits Johnson & Johnson with $2.1B deal to buy out Japan's Ci:zAdd another Big Pharma company to the wheeling and dealing inconsumer health: Johnson & Johnson is shelling out to take full control of Japanese cosmetics and skincare specialist Ci:z. J&J pl2018/10/23
-
Changsheng Bio-Technology fined $1.3bn after vaccine scandalsA Chinese drug watchdog has imposed a fine and asset seizure worth CNY9.1bn ($1.3bn) on Changsheng Bio-Technology following two major vaccine scandals. This amount includes a confiscation of the comp2018/10/22
-
Takeda gets Japanese approval for $62bn Shire acquisitionTakeda Pharmaceutical is close to completing the $62bn acquisition of Irish biopharmaceutical company Shire after receiving approval from the Japan Fair Trade Commission. The company agreedto acquire2018/10/22
-
Even in worst-case scenario, Roche will grow past biosimilar erosion in the U.S.: executiveRoche’s trio of megablockbuster cancer drugs, Herceptin, Rituxan and Avastin, still held their groundin the third quarter, despite a biosimilar onslaught in Europe. And though next year will be a diff2018/10/19
-
Amgen, Lilly migraine drugs nab Express Scripts backing, but Teva's shut outEarly into their hotly anticipated migraine launches, Amgen and Eli Lilly have picked up key coverage from Express Scripts, but Teva's Ajovy was left out in the cold. Express Scripts chose to cov2018/10/19
-
Can Pfizer's new breast cancer drug Talzenna really make a dent in the PARP field?The old adage “better late than never” may seem tired, but it could be apropos for Pfizer’s newly FDA-approved PARP inhibitor, Talzenna. Pfizer picked up the drug in its $14 billion acquisition of Med2018/10/18
-
Merck joins Novartis, GlaxoSmithKline in grabbing a consumer executive to beef up digitalMerck & Co. is joining the chief digital officer parade. The pharma giant has poached Jim Scholefield from Nike to head up its global IT and digital strategy, becoming the latest Big Pharma to put2018/10/18
-
US FDA grants ODD to Lynparza for treatment of pancreatic cancerThe US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for Lynparza(olaparib) to be used for the treatment of pancreatic cancer. Pancreatic cancer is a rare and life-thre2018/10/17
-
Immugenyx and Janssen to develop SLE model for drug developmentImmugenyx has signed a collaboration agreement with Janssen Research & Development to develop an in-vivo platform that will aid in treating systemic lupus erythematosus (SLE). Under the agreement2018/10/17